Tag:

Lipitor

Latest Headlines

Latest Headlines

AMA lines up against pharma's pay-to-delay deals

The Federal Trade Commission has a powerful new ally in its quest to quash "pay to delay" patent settlements: The American Medical Association. As Forbes reports, the doctors' association now officially supports legislation to outlaw the practice.

Merck gives up on prospective Januvia-Lipitor combo

Merck ($MRK) has doused development efforts on a new therapy combining its diabetes drug Januvia with a generic version of the cholesterol drug Lipitor.

Merck quietly scuttles another cholesterol combo program

Just three months after quietly snuffing its late-stage development program for the cholesterol combo MK-0524B, Merck has once again quietly doused development efforts on a new cholesterol therapy. MK-0431E, once in line for a 2014 regulatory filing, was killed for unspecified business reasons, according to Dow Jones.

Pfizer sales drop 16%, falling short of expectations

Once again, Lipitor's patent loss gave Pfizer's ($PFE) quarterly results a big wallop. The cholesterol fighter's sales plummeted by 71% year over year, to $749 million. That drop, if a bit bigger than anticipated, was expected; it's been expected for years. So, the company's 16% drop in sales, to about $14 billion, is no wake-up call.

Pfizer reps to bear brunt of Canadian layoffs

More job cuts at Pfizer ($PFE). The world's biggest drugmaker is shedding 300 from its Canadian workforce, or about 11% of its employees in the country. Hardest hit will be sales and marketing, particularly in primary care.

The 15 best-selling drugs of 2012

Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to...

Rise of the biologics has reshaped the list of top 15 drugs

Some of the biggest blockbusters known to the pharma industry have been swept off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition awaits to chop up markets. Barring the development of new megablockbusters this list is likely to remain stable for some time. That's positive for the companies and their investors. It will also help fund major R&D operations around the globe. And the drive to improve performance should continue to drive innovation. Click here to check out the full report >>

Danger for co-pay coupons: Medicare patients are using you

Forget the legal challenge to co-pay coupons filed by a group of health plans earlier this year. Forget the state of Massachusetts' coupon ban (it's been repealed now, anyway). The real threat to co-pay coupons may not be lawsuits from payers or outrage from insurance associations and pharmacy benefits managers.

U.S. consumers buy more, pay more for drugs

U.S. patients took more drugs and paid more for drugs last year and, according to a new analysis, that was because they have bad health habits and are depressed.

Big-name drugmakers play heart-drug roulette

Drugmakers from Merck to Sanofi to GlaxoSmithKline sink beaucoups bucks into three types of potential heart treatments.